FULC / Fulcrum Therapeutics, Inc. (FULC) Q2 2023 Earnings Call Transcript

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutica more_horizontal

Fulcrum Therapeutics, Inc. has had some key potential catalysts resolved positively recently. These included the FDA lifted the clinical hold on Fulcr more_horizontal

Fulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its pipeline candidate FTX-6058, to treat patients with sick more_horizontal

Fulcrum Therapeutics Inc (NASDAQ:FULC) is up 49.7% to trade at $5.87 at last glance -- its highest levels since March -- after the U.S. Food and Drug more_horizontal

Fulcrum Therapeutics (NASDAQ: FULC ) stock is on the rise Tuesday as investors react to positive news from the FDA. The big news here is the FDA lifte more_horizontal

Fulcrum Therapeutics announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) app more_horizontal

Fulcrum Utility Services Ltd (AIM:FCRM), the energy infrastructure group, shed more than two-thirds of its value on Monday after it announced it would more_horizontal

Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Chris Calabrese - LifeSci Ad more_horizontal